SCHEMBL20364801

SCHEMBL20364801

CC(C)COC(=O)N1CC2CN(C(C)C)CC2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.43
RAB9A P51151 1/20 0.42
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
HSD11B1 P28845 1/20 0.37
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
P2RX4 Q99571 1/20 0.36
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 2/20 0.35
KIT P10721 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
NR1H2 P55055 1/20 0.34
POLB P06746 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18375133 0.88 CHRM1 (0.42) HDAC2CHRNB2CHRNA4TSHRPOLB
SCHEMBL19308678 0.86 HDAC2 (0.44) HDAC2RAB9AKCNK3KCNK9CHRNB2
SCHEMBL20368920 0.81 HDAC2 (0.38) HDAC2RAB9AKCNK3KCNK9CHRNB2
SCHEMBL18374888 0.80 HDAC2 (0.40) HDAC2KCNK3KCNK9CHRNB2CHRNA4
SCHEMBL18374920 0.80 CHRNB2 (0.56) HDAC2CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL27373214 0.80 CHRNB2 (0.56) HDAC2CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1692767 0.80 RAB9A (0.45) HDAC2RAB9AKCNK3KCNK9CHRNB2
SCHEMBL16132847 0.80 CHRNB2 (0.56) HDAC2CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL14243062 0.80 CHRNB2 (0.54) HDAC2RAB9AKCNK3KCNK9CHRNB2
SCHEMBL13698848 0.79 RAB9A (0.46) HDAC2RAB9AKCNK3KCNK9CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421756-B2 Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase RODIN THERAPEUTICS, INC. (US) 2019-09-24 US disclosed
US-20180194760-A1 HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-07-12 US disclosed
US-20180194760-A1 HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194760-A1 HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE HDAC2, HDAC1, HDAC5 HDAC2 1/4885RAB9A 2071/4885KCNK3 3346/4885
US-10421756-B2 Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase HDAC2, HDAC1, HDAC5 HDAC2 1/4885RAB9A 2071/4885KCNK3 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.